ImmuPharma (LON:IMM) Shares Down 6.3% - Here's What Happened

Key Points

• ImmuPharma's shares dropped by 6.3% during mid-day trading, declining from a previous close of GBX 12.38 ($0.16) to a low of GBX 10.70 ($0.14).
• The company reported a net margin of 3,519.56% and a significant negative return on equity of -131.41% in its latest quarterly earnings.
• Analysts predict that ImmuPharma will post yearly earnings per share of -339.0000022, highlighting ongoing financial challenges.

ImmuPharma plc (LON:IMM - Get Free Report) dropped 6.3% during mid-day trading on Friday . The stock traded as low as GBX 10.70 ($0.14) and last traded at GBX 11.60 ($0.15). Approximately 3,961,091 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 8,360,403 shares. The stock had previously closed at GBX 12.38 ($0.16).

ImmuPharma Stock Down 6.3%

The company has a market cap of £58.32 million, a PE ratio of -13.03 and a beta of 1.53. The firm's fifty day simple moving average is GBX 8.75 and its 200-day simple moving average is GBX 4.62.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.